Sonnet Releases Virtual Investor "What This Means" Segment
1. Sonnet announces positive safety data for SON-1010 in clinical trials. 2. SON-1010 is being tested for advanced solid tumors and ovarian cancer. 3. Management discusses next steps post-trial results during investor segment. 4. Company collaborates with Roche for upcoming treatment studies. 5. Sonnet's FHAB platform aims to improve targeted cancer therapies.